menu
    • menu
    []

    Find Drugs for Genetic Disease in Phase II/ Phase III Clinical Development in DENMARK

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zealand Pharma

                            Denmark arrow
                            BioProcess International Europe
                            Not Confirmed

                            Zealand Pharma

                            Denmark arrow
                            BioProcess International Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasiglucagon

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon in Congenital Hyperinsulinism

                            Details : ZP4207 (dasiglucagon) subcutaneous injection is a glucagon receptor agonist and indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

                            Product Name : Zegalogue

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            June 30, 2023

                            Lead Product(s) : Dasiglucagon

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth